Home › Drugs by Condition › D › Diabetes, Type 2 › Repaglinide Alcohol & Food Interactions
Print Save or Share

Repaglinide and Alcohol / Food Interactions

Drug Interactions (812) Alcohol/Food Interactions (2) Disease Interactions (3)

There are 2 alcohol/food/lifestyle interactions with repaglinide which include:

Repaglinide and Alcohol (Ethanol)

Moderate Drug Interaction

GENERALLY AVOID: Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes. Hypoglycemia most frequently occurs with chronic drinking of large amounts of alcohol; however, it may also occur after binge drinking or moderate drinking, especially when the alcohol is ingested on an empty stomach. The mechanism is inhibition of gluconeogenesis and inhibition of the counterregulatory response to hypoglycemia. Hypoglycemia may last for 8 to 12 hours after ethanol ingestion. Chronic alcohol abuse may cause impaired glucose tolerance and hyperglycemia. Moderate alcohol consumption generally does not affect blood glucose levels in patients with well-controlled diabetes. In addition, a disulfiram-like reaction (flushing, headache, and nausea) has been reported frequently with chlorpropamide and very rarely with other sulfonylureas.

MANAGEMENT: Patients with diabetes should avoid alcohol if they experience flushing, headache, or nausea after alcohol ingestion, if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis. Patients with well-controlled diabetes should limit their intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz. wine, 12 oz. beer, or 1.5 oz. distilled spirits) in addition to their meal plan. The alcohol should be consumed with a meal.

Moderate Food Interaction

 

MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. However, the interaction seems to affect primarily those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability), presumably due to the fact that grapefruit juice inhibits intestinal rather than hepatic CYP450 3A4. Because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.

You should also know about...

repaglinide drug Interactions

There are 812 drug interactions with repaglinide

repaglinide disease Interactions

There are 3 disease interactions with repaglinide which include:

See also...

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.


Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web5)